Work

LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism

Year: 2011

Type: article

Source: Leukemia Research

DOI: 10.1016/j.leukres.2011.10.020

Authors: Roberto Rosato, Stefanie Hock, Paul Dent, Yun Dai, Steven Grant

Institutions: Virginia Commonwealth University, VCU Massey Comprehensive Cancer Center, Virginia Commonwealth University Medical Center

Language: English

Topic: Histone Deacetylase Inhibitors Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases

Awards: G131572022, G1353051725, G146968441, G1805530462, G2721733520, G299731492, G3148123924, G3518617075, G354229063, Signaling Pathways Regulating Epithelial Cell Survival, OSU-03012 therapy for glioblastoma, Flavopiridol / Bortezomib in Myeloma / B-Cell Neoplasms, G8382235333, Phase I Trial of Bortezomib and Romidepsin in CLL and Small Cell Lymphoma

OpenAlex ID: W2128617722

FWCI: 0.588

Cites: 38

Cited by: 13

Related to: 10